by Carolyn Haywood | Mar 1, 2019 | Briefings, UK
Background Genentech is the proprietor of European patent (UK) No. 1 641 822 entitled “Il-17A/F heterologous peptides and therapeutic uses thereof”. Genentech does not at present have a product covered by the patent but Lilly market an antibody under the...
by Carolyn Haywood | Nov 1, 2018 | Briefings, EPO
The two patent applications that were the subject of last week’s sequential hearings are both divisional applications of EP2771468 which was revoked in January 2018 and is currently under Appeal at the EPO. The two sequential hearings were consolidated with...
by Sean Hughes | Nov 1, 2016 | US & International
Introduction The Cancer Immunotherapy Pilot Program, also known as “Patents 4 Patients”, makes certain US patent applications relating to cancer immunotherapy eligible for special status and examination with the goal of completing prosecution within 12...
Recent Comments